Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

Obesity pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.

ClassNone selected
MechanismNone selected

No arms selected. Choose a drug, an arm, or a preset.

299 of 2118 arms with a reported figure. Choose arms to narrow the chart.

Drug, trialPopulationDoseWeeksEstimandComparatorBaseline weightMean changeComparator deltaHbA1c
Semaglutide 2.4 mgSTEP 1Obesity or overweight2.4 mg68ITTplacebon/r-14.9%-12.4n/r
Semaglutide Semaglutide placeboSTEP 1Obesity or overweightn/r68ITTThis arm is placebon/r-2.4%n/rn/r
Semaglutide 7.2 mgSTEP UPObesity or overweight7.2 mg72ITTplacebon/r-18.8%-14.9n/r
Semaglutide 2.4 mgSTEP UPObesity or overweight2.4 mg72ITTplacebon/r-15.5%n/rn/r
Semaglutide PlaceboSTEP UPObesity or overweightn/r72ITTThis arm is placebon/r-3.9%n/rn/r
Semaglutide SemaglutideSELECTObesity or overweightn/r4ITTplacebon/rn/rn/r-0.31 Percentage of HbA1c
Semaglutide Placebo (semaglutide)SELECTObesity or overweightn/r4ITTThis arm is placebon/rn/rn/r0.01 Percentage of HbA1c
Semaglutide 1.0 mgSTEP 2Obesity or overweight1.0 mg4ITTplacebon/rn/rn/r-1.5 Percentage point of HbA1c
Semaglutide 2.4 mgSTEP 2Obesity or overweight2.4 mg4ITTplacebon/rn/rn/r-1.7 Percentage point of HbA1c
Semaglutide Semaglutide placebo I/IISTEP 2Obesity or overweightn/r4ITTThis arm is placebon/rn/rn/r-0.3 Percentage point of HbA1c
Semaglutide SemaglutideSTEP 4Obesity or overweightn/r20Efficacyplacebon/r-8.3%n/rn/r
Semaglutide PlaceboSTEP 4Obesity or overweightn/r20EfficacyThis arm is placebon/r6.5%n/rn/r
Semaglutide 2.4 mgSTEP 4Obesity or overweight2.4 mg20ITTn/rn/rn/rn/r-0.2 Percentage point of HbA1c
Semaglutide Placebo, in trialSTEP 4Obesity or overweightn/r20ITTThis arm is placebon/rn/rn/r0.1 Percentage point of HbA1c
Semaglutide 15 mgSURMOUNT-5Obesity or overweight15 mg72n/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgSURMOUNT-5Obesity or overweight2.4 mg72n/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgSTEP HFpEF DMT2D only2.4 mg1ITTplacebon/rn/rn/r-0.8 Percentage of HbA1c
Semaglutide Semaglutide placebo OWSTEP HFpEF DMT2D onlyn/r1ITTThis arm is placebon/rn/rn/r0.1 Percentage of HbA1c
Semaglutide SemaglutideSTEP 3Obesity or overweightn/r4Efficacyplacebon/rn/rn/rn/r
Semaglutide Semaglutide placeboSTEP 3Obesity or overweightn/r4EfficacyThis arm is placebon/rn/rn/rn/r
Semaglutide 2.4 mgSTEP 3Obesity or overweight2.4 mgn/rITTn/rn/rn/rn/r-0.5 Percentage point of HbA1c
Semaglutide Placebo, in trialSTEP 3Obesity or overweightn/rn/rITTThis arm is placebon/rn/rn/r-0.3 Percentage point of HbA1c
Semaglutide Insuline glargine U100 (reduced) + semaglutideA Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SObesity + T2Dn/rn/rn/rn/rn/rn/rn/r-1.37 Percentage point of HbA1c
Semaglutide Insuline glargine U100 (titrated)A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SObesity + T2Dn/rn/rn/rn/rn/rn/rn/r-0.65 Percentage point of HbA1c
Semaglutide SemaglutideSTEP-HFpEFObesity or overweightn/r59ITTplacebon/rn/rn/rn/r
Semaglutide Placebo (semaglutide)STEP-HFpEFObesity or overweightn/r59ITTThis arm is placebon/rn/rn/rn/r
Semaglutide 7.2 mgA Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightObesity + T2D7.2 mg72n/rplacebon/rn/rn/r-1.8 Percentage of HbA1c
Semaglutide 2.4 mgA Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightObesity + T2D2.4 mg72n/rplacebon/rn/rn/r-1.7 Percentage of HbA1c
Semaglutide PlaceboA Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightObesity + T2Dn/r72n/rThis arm is placebon/rn/rn/r-0.3 Percentage of HbA1c
Semaglutide 2.4 mgResearch Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee OsteoarthritisObesity or overweight2.4 mgn/rITTplacebon/rn/rn/rn/r
Semaglutide 2.4 mgResearch Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee OsteoarthritisObesity or overweight2.4 mgn/rITTThis arm is placebon/rn/rn/rn/r
Semaglutide 2.4 mgSTEP 6Obesity or overweight2.4 mg68ITTplacebon/rn/rn/r-1 Percentage of HbA1c
Semaglutide 2.4 mgSTEP 6Obesity or overweight2.4 mg68ITTThis arm is placebon/rn/rn/r0 Percentage of HbA1c
Semaglutide 1.7 mgSTEP 6Obesity or overweight1.7 mg68ITTplacebon/rn/rn/r-0.9 Percentage of HbA1c
Semaglutide 1.7 mgSTEP 6Obesity or overweight1.7 mg68n/rThis arm is placebon/rn/rn/rn/r
Semaglutide SemaglutideSTEP7Obesity + T2Dn/r44ITTplacebon/rn/rn/r-0.8 Percentage of HbA1c
Semaglutide Placebo (semaglutide)STEP7Obesity + T2Dn/r44ITTThis arm is placebon/rn/rn/r-0.1 Percentage of HbA1c
Semaglutide SemaglutideSTEP 5Obesity or overweightn/r4Efficacyplacebon/rn/rn/rn/r
Semaglutide PlaceboSTEP 5Obesity or overweightn/r4EfficacyThis arm is placebon/rn/rn/rn/r
Semaglutide 2.4 mgSTEP 5Obesity or overweight2.4 mgn/rITTn/rn/rn/rn/r-0.5 Percent of glycated haemoglobin
Semaglutide Placebo, in trialSTEP 5Obesity or overweightn/rn/rITTThis arm is placebon/rn/rn/r-0.1 Percent of glycated haemoglobin
Semaglutide PlaceboSTEP12Obesity or overweightn/r44n/rThis arm is placebon/rn/rn/r0 Percentage of HbA1c
Semaglutide 2.4 mgSTEP12Obesity or overweight2.4 mgn/rn/rn/rn/rn/rn/r-0.4 Percentage of HbA1c
Semaglutide SemaglutideSTEP 10Obesity or overweightn/r52ITTplacebon/rn/rn/r-0.4 Percentage of HbA1c
Semaglutide Placebo (semaglutide)STEP 10Obesity or overweightn/r52ITTThis arm is placebon/rn/rn/r0.1 Percentage of HbA1c
Semaglutide SemaglutideA Research Study on How Well Semaglutide Works in Adolescents With Overweight or ObesityObesity or overweightn/r16ITTplacebon/rn/rn/r-0.4 Percentage of HbA1c
Semaglutide PlaceboA Research Study on How Well Semaglutide Works in Adolescents With Overweight or ObesityObesity or overweightn/r16ITTThis arm is placebon/rn/rn/r-0.1 Percentage of HbA1c
Semaglutide 2.4 mgResearch Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With ObesityObesity or overweight2.4 mg50ITTplacebon/rn/rn/r-0.4 Percentage of HbA1c
Semaglutide PlaceboResearch Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With ObesityObesity or overweightn/r50ITTThis arm is placebon/rn/rn/r0 Percentage of HbA1c
Semaglutide Semaglutide, on treatmentResearch Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With ObesityObesity or overweightn/r44Efficacyn/rn/rn/rn/rn/r
Semaglutide Placebo, on treatmentResearch Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With ObesityObesity or overweightn/r44EfficacyThis arm is placebon/rn/rn/rn/r
Tirzepatide PlaceboSURMOUNT-1Obesity, no T2Dn/r72ITTThis arm is placebon/r-3.1%n/rn/r
Tirzepatide 5 mgSURMOUNT-1Obesity, no T2D5 mg72ITTplacebon/r-15%-11.9n/r
Tirzepatide 10 mgSURMOUNT-1Obesity, no T2D10 mg72ITTplacebon/r-19.5%-16.4n/r
Tirzepatide 15 mgSURMOUNT-1Obesity, no T2D15 mg72ITTplacebon/r-20.9%-17.8n/r
Tirzepatide 15 mgSURMOUNT-2Obesity + T2D15 mg79n/rplacebon/rn/rn/rn/r
Tirzepatide PlaceboSURMOUNT-2Obesity + T2Dn/r79n/rThis arm is placebon/rn/rn/rn/r
Tirzepatide 10 mgSURMOUNT-2Obesity + T2D10 mg72n/rn/rn/rn/rn/rn/r
Tirzepatide Tirzepatide (lead-in)SURMOUNT-4Obesity or overweightn/r36n/rplacebon/rn/rn/rn/r
Tirzepatide Tirzepatide MTDSURMOUNT-4Obesity or overweightn/r36n/rplacebon/rn/rn/rn/r
Tirzepatide PlaceboSURMOUNT-4Obesity or overweightn/r36n/rThis arm is placebon/rn/rn/rn/r
Tirzepatide TirzepatideA Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialObesity or overweightn/r4n/rplacebon/rn/rn/rn/r
Tirzepatide PlaceboA Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialObesity or overweightn/r4n/rThis arm is placebon/rn/rn/rn/r
Tirzepatide TirzepatideSURMOUNT-3Obesity or overweightn/r72n/rplacebon/rn/rn/rn/r
Tirzepatide PlaceboSURMOUNT-3Obesity or overweightn/r72n/rThis arm is placebon/rn/rn/rn/r
Tirzepatide Tirzepatide MTD_GPI1SURMOUNT-OSAObesity or overweightn/r52n/rplacebon/rn/rn/rn/r
Tirzepatide Placebo_GPI1SURMOUNT-OSAObesity or overweightn/r52n/rThis arm is placebon/rn/rn/rn/r
Tirzepatide Tirzepatide MTD_GPI2SURMOUNT-OSAObesity or overweightn/r52n/rplacebon/rn/rn/rn/r
Tirzepatide Placebo_GPI2SURMOUNT-OSAObesity or overweightn/r52n/rThis arm is placebon/rn/rn/rn/r
Tirzepatide 15 mgSURMOUNT-JObesity or overweight15 mg72n/rplacebon/rn/rn/rn/r
Tirzepatide PlaceboSURMOUNT-JObesity or overweightn/r72n/rThis arm is placebon/rn/rn/rn/r
Tirzepatide 10 mgSURMOUNT-JObesity or overweight10 mg72n/rn/rn/rn/rn/rn/r
Tirzepatide 15 mgSURMOUNT-CNObesity or overweight15 mg52n/rplacebon/rn/rn/rn/r
Tirzepatide PlaceboSURMOUNT-CNObesity or overweightn/r52n/rThis arm is placebon/rn/rn/rn/r
Tirzepatide 10 mgSURMOUNT-CNObesity or overweight10 mg52n/rn/rn/rn/rn/rn/r
Orforglipron PlaceboATTAIN-2Obesity + T2Dn/r72n/rThis arm is placebon/rn/rn/rn/r
Orforglipron 6 mgATTAIN-2Obesity + T2D6 mg72n/rplacebon/rn/rn/rn/r
Orforglipron 12 mgATTAIN-2Obesity + T2D12 mg72n/rplacebon/rn/rn/rn/r
Orforglipron Placebo QDATTAIN-JObesity or overweightn/r72n/rThis arm is placebon/rn/rn/rn/r
Orforglipron 6 mgATTAIN-JObesity or overweight6 mg72n/rplacebon/rn/rn/rn/r
Orforglipron 12 mgATTAIN-JObesity or overweight12 mg72n/rplacebon/rn/rn/rn/r
Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mgREDEFINE 1Obesity, no T2Dcagrilintide 2.4 mg and semaglutide 2.4 mg68n/rplacebon/r-20.4%-17.3n/r
Cagrilintide/semaglutide Placebo s.c.REDEFINE 1Obesity, no T2Dn/r68n/rThis arm is placebon/r-3%n/rn/r
Retatrutide 4 mgTRIUMPH-1Obesity, no T2D4 mg80ITTplacebon/r-17.6%n/rn/r
Retatrutide 9 mgTRIUMPH-1Obesity, no T2D9 mg80ITTplacebon/r-23.7%-19.8n/r
Retatrutide 12 mgTRIUMPH-1Obesity, no T2D12 mg80ITTplacebon/r-25%-21n/r
Retatrutide PlaceboTRIUMPH-1Obesity, no T2Dn/r80ITTThis arm is placebon/r-3.9%n/rn/r
Survodutide 3.6 mgSYNCHRONIZE-1Obesity + T2D3.6 mg76ITTplacebon/r-12.2%n/rn/r
Survodutide 6.0 mgSYNCHRONIZE-1Obesity + T2D6.0 mg76ITTplacebon/r-13%n/rn/r
Survodutide PlaceboSYNCHRONIZE-1Obesity + T2Dn/r76ITTThis arm is placebon/r-5.4%n/rn/r
Survodutide 0.6 mgA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightObesity or overweight0.6 mg46Efficacyplacebon/rn/rn/rn/r
Survodutide Placebo groupA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightObesity or overweightn/r46EfficacyThis arm is placebon/rn/rn/rn/r
Survodutide 2.4 mgA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightObesity or overweight2.4 mg46Efficacyplacebon/rn/rn/rn/r
Survodutide 3.6 mgA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightObesity or overweight3.6 mg46Efficacyplacebon/rn/rn/rn/r
Survodutide 4.8 mgA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightObesity or overweight4.8 mg46Efficacyplacebon/rn/rn/rn/r
VK2735 2.5 mgVENTUREObesity, no T2D2.5 mg13n/rplacebon/r-9.1%n/rn/r
VK2735 15 mgVENTUREObesity, no T2D15 mg13n/rplacebon/r-14.7%n/rn/r
VK2735 Placebo 13 weeksVENTUREObesity, no T2Dn/r13n/rThis arm is placebon/r-1.7%n/rn/r
Eloralintide PlaceboNCT06230523Obesity, no T2Dn/r48EfficacyThis arm is placebon/r-0.4%n/rn/r
Eloralintide 1 mgNCT06230523Obesity, no T2D1 mg48Efficacyplacebon/r-9%n/rn/r
Eloralintide 3 mgNCT06230523Obesity, no T2D3 mg48Efficacyplacebon/r-12%n/rn/r
Eloralintide 6 mgNCT06230523Obesity, no T2D6 mg48Efficacyplacebon/r-18%n/rn/r
Eloralintide 9 mgNCT06230523Obesity, no T2D9 mg48Efficacyplacebon/r-20%n/rn/r
Berobenatide PlaceboVESPER-1Obesity or overweightn/r28n/rThis arm is placebon/rn/rn/rn/r
Dulaglutide Dulaglutide ArmMetabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery PatientsStress Hyperglycemian/rn/rn/rplacebon/rn/rn/rn/r
Dulaglutide Placebo ArmMetabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery PatientsStress Hyperglycemian/rn/rn/rThis arm is placebon/rn/rn/rn/r
Exenatide Group AEffect on Weight Loss of Exenatide Versus PlaceboT2D onlyn/rn/rn/rplacebon/rn/rn/rn/r
Exenatide Group BEffect on Weight Loss of Exenatide Versus PlaceboT2D onlyn/rn/rn/rn/rn/rn/rn/rn/r
Exenatide ExenatideThe Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese SubjectsObesity or overweightn/r5n/rplacebon/rn/rn/rn/r
Exenatide PlaceboThe Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese SubjectsObesity or overweightn/r5n/rThis arm is placebon/rn/rn/rn/r
Exenatide Exenatide once weekly (EQW )EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)Obesity or overweightn/r4n/rn/rn/r3.8%n/rn/r
Exenatide Dapagliflozin (DAPA)EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)Obesity or overweightn/r4n/rn/rn/r1.5%n/rn/r
Exenatide EQW plus DAPAEQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)Obesity or overweightn/r4n/rn/rn/r6.9%n/rn/r
Exenatide Dapagliflozin plus Glucophage (MET ER)EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)Obesity or overweightn/r4n/rn/rn/r1.7%n/rn/r
Exenatide Phentermine /Topiramate (PHEN/ TPM) EREQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)Obesity or overweightn/r4n/rn/rn/r8.1%n/rn/r
Exenatide Exenatide once weekly extended-releaseECHOObesity or overweightn/r36n/rplacebon/r1.7%n/rn/r
Exenatide Matching placeboECHOObesity or overweightn/r36n/rThis arm is placebon/r3.5%n/rn/r
Exenatide Group AA Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese PatientsObesity or overweightn/r24n/rplacebon/rn/rn/rn/r
Exenatide Group BA Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese PatientsObesity or overweightn/r24n/rn/rn/rn/rn/rn/r
Liraglutide 3.0mgEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesObesity or overweight3.0mg68n/rplacebon/r0.69%n/rn/r
Liraglutide 3.0mgEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesObesity or overweight3.0mg68n/rn/rn/r2.91%n/rn/r
Liraglutide Liraglutide Placebo, no Pre-diabetesEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesObesity or overweightn/r68n/rThis arm is placebon/r0.28%n/rn/r
Liraglutide Liraglutide Placebo, Pre-diabetesEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesObesity or overweightn/r68EfficacyThis arm is placebon/rn/rn/rn/r
Liraglutide 3.0 mgEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesObesity or overweight3.0 mg56Efficacyn/rn/rn/rn/rn/r
Liraglutide 3.0 mgEffect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - DiabetesObesity or overweight3.0 mg56n/rplacebon/r2.3%n/r-1.3 percentage point change of HbA1c
Liraglutide 1.8 mgEffect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - DiabetesObesity or overweight1.8 mg56n/rplacebon/r2%n/r-1.1 percentage point change of HbA1c
Liraglutide PlaceboEffect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - DiabetesObesity or overweightn/r56n/rThis arm is placebon/r-0.1%n/r-0.3 percentage point change of HbA1c
Liraglutide 3.0 mgComparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - MaintenanceObesity or overweight3.0 mgn/rn/rplacebon/rn/rn/rn/r
Liraglutide PlaceboComparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - MaintenanceObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Liraglutide 3.0 mgSCALE™ InsulinObesity or overweight3.0 mg56Efficacyplacebon/rn/rn/r-1.1 Percentage of HbA1c
Liraglutide PlaceboSCALE™ InsulinObesity or overweightn/r56EfficacyThis arm is placebon/rn/rn/r-0.5 Percentage of HbA1c
Liraglutide 3.0 mgEffect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep ApnoeaObesity or overweight3.0 mg32n/rplacebon/rn/rn/r-0.36 percentage of glycosylated haemoglobin
Liraglutide PlaceboEffect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep ApnoeaObesity or overweightn/r32n/rThis arm is placebon/rn/rn/r-0.17 percentage of glycosylated haemoglobin
Liraglutide SemaglutideSTEP 8Obesity or overweightn/r68ITTplacebon/rn/rn/r-0.3 Percenatge of HbA1c
Liraglutide LiraglutideSTEP 8Obesity or overweightn/r68ITTplacebon/rn/rn/r-0.1 Percenatge of HbA1c
Liraglutide Placebo (liraglutide)STEP 8Obesity or overweightn/r68ITTThis arm is placebon/rn/rn/r0.1 Percenatge of HbA1c
Liraglutide LiraglutideSCALE™ IBTObesity or overweightn/r56Efficacyplacebon/rn/rn/rn/r
Liraglutide PlaceboSCALE™ IBTObesity or overweightn/r56EfficacyThis arm is placebon/rn/rn/rn/r
Liraglutide 3.0 mgSCALE™ IBTObesity or overweight3.0 mg56ITTn/rn/rn/rn/r-0.2 percentage
Liraglutide Placebo, in trialSCALE™ IBTObesity or overweightn/r56ITTThis arm is placebon/rn/rn/r-0.1 percentage
Liraglutide LiraglutideEffect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With ObesityObesity or overweightn/rn/rn/rplacebon/rn/rn/r-0.1 Percentage of HbA1c
Liraglutide PlaceboEffect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With ObesityObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/r0 Percentage of HbA1c
Liraglutide Metformin XR plus liraglutideCombined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)T2D onlyn/r84n/rplacebon/r-7.2%n/rn/r
Liraglutide Metformin XR plus placeboCombined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)T2D onlyn/r84n/rThis arm is placebon/r-3.1%n/rn/r
Liraglutide Liraglutide Pen Injector (Saxenda)SAXAPCOSObesity + T2Dn/r1n/rplacebon/r5.7%n/rn/r
Liraglutide Placebo liraglutide pen injectorSAXAPCOSObesity + T2Dn/r1n/rThis arm is placebon/r1.4%n/rn/r
Liraglutide LiraglutideEffect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeObesity or overweightn/rn/rn/rplacebon/rn/rn/r-0.2 Percentage point of HbA1c
Liraglutide PlaceboEffect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/r0 Percentage point of HbA1c
Liraglutide 0.05 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusObesity or overweight0.05 mg52ITTThis arm is placebon/rn/rn/rn/r
Liraglutide 0.1 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusObesity or overweight0.1 mg52ITTThis arm is placebon/rn/rn/rn/r
Liraglutide 0.2 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusObesity or overweight0.2 mg52ITTThis arm is placebon/rn/rn/rn/r
Liraglutide 0.3 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusObesity or overweight0.3 mg52ITTThis arm is placebon/rn/rn/rn/r
Liraglutide 0.4 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusObesity or overweight0.4 mg52ITTThis arm is placebon/rn/rn/rn/r
Liraglutide 3.0 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusObesity or overweight3.0 mg52ITTThis arm is placebon/rn/rn/rn/r
Liraglutide Placebo + MetforminA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesT2D onlyn/r14n/rThis arm is placebon/rn/rn/rn/r
Liraglutide Liraglutide + MetforminA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesT2D onlyn/rn/rn/rplacebon/rn/rn/rn/r
Liraglutide 100 mcgA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesT2D only100 mcg14n/rn/rn/rn/rn/rn/r
Liraglutide 200 mcgA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesT2D only200 mcg14n/rn/rn/rn/rn/rn/r
Liraglutide 300 mcgA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesT2D only300 mcg14n/rn/rn/rn/rn/rn/r
Liraglutide 2.4 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.Obesity or overweight2.4 mg26ITTThis arm is placebon/rn/rn/r-0.1 Percentage point of HbA1c
Liraglutide 4.5 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.Obesity or overweight4.5 mg26ITTThis arm is placebon/rn/rn/r-0.1 Percentage point of HbA1c
Liraglutide 1.2 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.Obesity or overweight1.2 mg26ITTThis arm is placebon/rn/rn/r-0.1 Percentage point of HbA1c
Liraglutide 0.6 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.Obesity or overweight0.6 mg26ITTThis arm is placebon/rn/rn/r-0.1 Percentage point of HbA1c
Liraglutide 0.3 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.Obesity or overweight0.3 mg26ITTThis arm is placebon/rn/rn/r0 Percentage point of HbA1c
Liraglutide 3.0 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.Obesity or overweight3.0 mg26ITTplacebon/rn/rn/r-0.3 Percentage point of HbA1c
Liraglutide 3.0 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.Obesity or overweight3.0 mg26ITTThis arm is placebon/rn/rn/r-0.1 Percentage point of HbA1c
Liraglutide 3.0 mgThe Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesObesity or overweight3.0 mgn/rn/rn/rn/rn/rn/r5.6 percentage (%) of total haemoglobin
Liraglutide 3.0 mgThe Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesObesity or overweight3.0 mgn/rn/rplacebon/rn/rn/r5.58 percentage (%) of total haemoglobin
Liraglutide 3.0 mgThe Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesObesity or overweight3.0 mgn/rn/rplacebon/rn/rn/r5.6 percentage (%) of total haemoglobin
Liraglutide 3.0 mgThe Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesObesity or overweight3.0 mgn/rn/rplacebon/rn/rn/r5.57 percentage (%) of total haemoglobin
Liraglutide OrlistatThe Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesObesity or overweightn/rn/rn/rplacebon/rn/rn/r5.55 percentage (%) of total haemoglobin
Lixisenatide Lixisenatide24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 YearsT2D onlyn/r24Efficacyn/rn/rn/rn/rn/r
Lixisenatide Sitagliptin24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 YearsT2D onlyn/r24Efficacyn/rn/rn/rn/rn/r
Mazdutide 3/6 Milligrams (mg) MazdutideA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightObesity or overweightn/rn/rn/rplacebon/rn/rn/rn/r
Mazdutide 10 mgA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightObesity or overweight10 mg32n/rplacebon/r96.1%n/rn/r
Mazdutide 16 mgA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightObesity or overweight16 mg32n/rplacebon/r92.23%n/rn/r
Mazdutide PlaceboA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightObesity or overweightn/r32n/rThis arm is placebon/r23.97%n/rn/r
Mazdutide 6 mgA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightObesity or overweight6 mg32n/rn/rn/r67.64%n/rn/r
Oral Semaglutide Oral semaglutideOASIS 1Obesity or overweightn/r1n/rplacebon/rn/rn/r-0.2 Percentage of HbA1c
Oral Semaglutide Oral semaglutide placeboOASIS 1Obesity or overweightn/r1n/rThis arm is placebon/rn/rn/r0.1 Percentage of HbA1c
Oral Semaglutide 25 mgOASIS 4Obesity or overweight25 mgn/rn/rplacebon/rn/rn/r-0.3 Percentage of HbA1c
Oral Semaglutide Oral semaglutide placeboOASIS 4Obesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/r0 Percentage of HbA1c
Oral Semaglutide 50 mgOASIS 2Obesity or overweight50 mg68ITTplacebon/rn/rn/r-0.8 Change in HbA1c (%)
Oral Semaglutide oral semaglutide placebo once dailyOASIS 2Obesity or overweightn/r68ITTThis arm is placebon/rn/rn/r0 Change in HbA1c (%)
TERN-601 250 mgFALCONObesity or overweight250 mgn/rn/rplacebon/rn/rn/rn/r
TERN-601 500 mgFALCONObesity or overweight500 mgn/rn/rplacebon/rn/rn/rn/r
TERN-601 750 mgFALCONObesity or overweight750 mgn/rn/rplacebon/rn/rn/rn/r
TERN-601 Matching PlaceboFALCONObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
CT-868 CT-868 PlaceboA Study of CT-868 in Type 1 Diabetes MellitusObesity + T2Dn/r16n/rThis arm is placebon/rn/rn/rn/r
CT-868 1.8 mgA Study of CT-868 in Type 1 Diabetes MellitusObesity + T2D1.8 mg16n/rn/rn/rn/rn/rn/r
CT-868 4.1 mgA Study of CT-868 in Type 1 Diabetes MellitusObesity + T2D4.1 mg16n/rn/rn/rn/rn/rn/r
CT-868 6.6 mgA Study of CT-868 in Type 1 Diabetes MellitusObesity + T2D6.6 mg16n/rn/rn/rn/rn/rn/r
HM15211 HM15211A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLDNAFLDn/rn/rn/rplacebon/rn/rn/rn/r
HM15211 PlaceboA Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLDNAFLDn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Pramlintide Placebo-P + Placebo-MStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Pramlintide 360 mcgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsObesity or overweight360 mcgn/rn/rThis arm is placebon/rn/rn/rn/r
Pramlintide 5.0 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsObesity or overweight5.0 mgn/rn/rThis arm is placebon/rn/rn/rn/r
Pramlintide 2.5 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsObesity or overweight2.5 mgn/rn/rplacebon/rn/rn/rn/r
Pramlintide 5.0 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsObesity or overweight5.0 mgn/rn/rplacebon/rn/rn/rn/r
Pramlintide 1.25 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsObesity or overweight1.25 mgn/rn/rplacebon/rn/rn/rn/r
Pramlintide 2.5 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsObesity or overweight2.5 mgn/rn/rplacebon/rn/rn/rn/r
Pramlintide 5.0 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsObesity or overweight5.0 mgn/rn/rplacebon/rn/rn/rn/r
Pramlintide 1Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinObesity or overweightn/rn/rn/rn/rn/rn/rn/rn/r
Pramlintide 2Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinObesity or overweightn/rn/rn/rplacebon/rn/rn/rn/r
Pramlintide 3Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinObesity or overweightn/rn/rn/rplacebon/rn/rn/rn/r
Pramlintide PlaceboA Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Pramlintide Pramlintide + MetreleptinA Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsObesity or overweightn/rn/rn/rn/rn/rn/rn/rn/r
Pramlintide Pramlintide Acetate and PlaceboA Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese SubjectsObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Pramlintide Lead-In PeriodA Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese SubjectsObesity or overweightn/rn/rn/rplacebon/rn/rn/rn/r
Bimagrumab 30 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseObesity or overweight30 mg4n/rThis arm is placebon/rn/rn/rn/r
Bimagrumab 30 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseObesity or overweight30 mg4n/rplacebon/rn/rn/rn/r
Bimagrumab 30 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseObesity or overweight30 mg4n/rplacebon/rn/rn/rn/r
Bimagrumab 1.0 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseObesity or overweight1.0 mg4n/rThis arm is placebon/rn/rn/rn/r
Bimagrumab 2.4 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseObesity or overweight2.4 mg4n/rThis arm is placebon/rn/rn/rn/r
Bimagrumab 1.0 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseObesity or overweight1.0 mg4n/rplacebon/rn/rn/rn/r
Bimagrumab 2.4 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseObesity or overweight2.4 mg4n/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion NB16A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese SubjectsObesity or overweightn/r56n/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion NB32A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese SubjectsObesity or overweightn/r56n/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion PlaceboA Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese SubjectsObesity or overweightn/r56n/rThis arm is placebon/rn/rn/rn/r
Naltrexone And Bupropion NB32A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese SubjectsObesity or overweightn/r28n/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion PlaceboA Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese SubjectsObesity or overweightn/r28n/rThis arm is placebon/rn/rn/rn/r
Naltrexone And Bupropion NB32A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification ProgramObesity or overweightn/r56n/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion PlaceboA Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification ProgramObesity or overweightn/r56n/rThis arm is placebon/rn/rn/rn/r
Naltrexone And Bupropion NB32A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 DiabetesObesity + T2Dn/r56n/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion PlaceboA Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 DiabetesObesity + T2Dn/r56n/rThis arm is placebon/rn/rn/rn/r
Naltrexone And Bupropion BWL + NB medicationBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute TreatmentObesity or overweightn/r16n/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion BWL + PlaceboBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute TreatmentObesity or overweightn/r16n/rThis arm is placebon/rn/rn/rn/r
Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medicationPharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)Obesity or overweightn/r16n/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion BWL + PlaceboPharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)Obesity or overweightn/r16n/rThis arm is placebon/rn/rn/rn/r
Naltrexone And Bupropion NB medicationBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance TherapyObesity or overweightn/r16n/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion PlaceboBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance TherapyObesity or overweightn/r16n/rThis arm is placebon/rn/rn/rn/r
Naltrexone And Bupropion Naltrexone+Bupropion MedicationPharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)Obesity or overweightn/rn/rn/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion PlaceboPharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)Obesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Naltrexone And Bupropion Naltrexone/BupropionCognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-RespondersObesity or overweightn/rn/rn/rplacebon/rn/rn/rn/r
Naltrexone And Bupropion PlaceboCognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-RespondersObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Orlistat Intensive Lifestyle Mod. InterventionFIT-PLESEInfertility, Femalen/rn/rn/rplacebon/rn/rn/rn/r
Orlistat Standard Lifestyle InterventionFIT-PLESEInfertility, Femalen/rn/rn/rn/rn/rn/rn/rn/r
Orlistat PlaceboSafety and Efficacy of Xenical in Children and Adolescents With Obesity-Related DiseasesObesity + T2Dn/r12n/rThis arm is placebon/rn/rn/rn/r
Orlistat OrlistatSafety and Efficacy of Xenical in Children and Adolescents With Obesity-Related DiseasesObesity + T2Dn/r12n/rplacebon/rn/rn/rn/r
Phentermine And Topiramate VI-0521 LowStudy of VI-0521 Compared to Placebo in Treatment of Obesity in AdultsObesity or overweightn/r56n/rplacebon/rn/rn/rn/r
Phentermine And Topiramate VI-0521 TopStudy of VI-0521 Compared to Placebo in Treatment of Obesity in AdultsObesity or overweightn/r56n/rplacebon/rn/rn/rn/r
Phentermine And Topiramate PlaceboStudy of VI-0521 Compared to Placebo in Treatment of Obesity in AdultsObesity or overweightn/r56n/rThis arm is placebon/rn/rn/rn/r
Phentermine And Topiramate VI-0521 TopA Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsObesity or overweightn/r28n/rplacebon/rn/rn/rn/r
Phentermine And Topiramate VI-0521 MidA Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsObesity or overweightn/r28n/rplacebon/rn/rn/rn/r
Phentermine And Topiramate TPM 46A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsObesity or overweightn/r28n/rplacebon/rn/rn/rn/r
Phentermine And Topiramate TPM 92A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsObesity or overweightn/r28n/rplacebon/rn/rn/rn/r
Phentermine And Topiramate PHEN 7.5A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsObesity or overweightn/r28n/rplacebon/rn/rn/rn/r
Phentermine And Topiramate PHEN 15A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsObesity or overweightn/r28n/rplacebon/rn/rn/rn/r
Phentermine And Topiramate PlaceboA Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsObesity or overweightn/r28n/rThis arm is placebon/rn/rn/rn/r
Phentermine And Topiramate LSMT 12SMARTObesity or overweightn/rn/rn/rn/rn/rn/rn/rn/r
Phentermine And Topiramate LSMT 24SMARTObesity or overweightn/rn/rn/rn/rn/rn/rn/rn/r
Phentermine And Topiramate Phentermine & TopiramateAdjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year OldsObesity or overweightn/r12n/rplacebon/rn/rn/r0.05 Percentage of glycated hemoglobin
Phentermine And Topiramate Placebo DrugsAdjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year OldsObesity or overweightn/r12n/rThis arm is placebon/rn/rn/r0.1 Percentage of glycated hemoglobin
Phentermine And Topiramate SemaglutideA Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaObesity or overweightn/r52n/rn/rn/rn/rn/rn/r
Phentermine And Topiramate Other anti-obesity medicationA Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaObesity or overweightn/r52n/rn/rn/rn/rn/rn/r
Setmelanotide SetmelanotideLong Term Extension Trial of SetmelanotideObesity or overweightn/rn/rn/rn/rn/rn/rn/rn/r
Setmelanotide PlaceboA Trial of Setmelanotide in Acquired Hypothalamic ObesityObesity or overweightn/r52n/rThis arm is placebon/rn/rn/rn/r
Setmelanotide SetmelanotideA Trial of Setmelanotide in Acquired Hypothalamic ObesityObesity or overweightn/r52n/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotide (Double-Blind)Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityBardet Biedl Syndrome (BBS); Alström Syndrome...n/r52n/rplacebon/rn/rn/rn/r
Setmelanotide Placebo (Double-Blind)Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityBardet Biedl Syndrome (BBS); Alström Syndrome...n/r52n/rThis arm is placebon/rn/rn/rn/r
Setmelanotide Setmelanotide (Open-label)Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityBardet Biedl Syndrome (BBS); Alström Syndrome...n/r52n/rplacebon/rn/rn/rn/r
Setmelanotide Pivotal CohortSetmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityBardet Biedl Syndrome (BBS); Alström Syndrome...n/r52n/rn/rn/r-5.21%n/rn/r
Setmelanotide 2 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency2 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide 2.5 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency2.5 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide 3 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency3 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide 20 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency20 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide 25 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency25 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide 3 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency3 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide 30 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency30 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide 20 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency20 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide 25 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency25 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide 30 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayBardet-Biedl Syndrome; POMC Deficiency30 mg1n/rn/rn/rn/rn/rn/r
Setmelanotide SetmelanotideSetmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityObesity or overweightn/r12n/rn/rn/r-12.34%n/rn/r
Setmelanotide SetmelanotideSetmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityObesity or overweightn/r12n/rn/rn/r-25.83%n/rn/r
Setmelanotide Setmelanotide: PPL GroupSetmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityObesity or overweightn/r2n/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotide: BBS GroupSetmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityObesity or overweightn/r2n/rn/rn/rn/rn/rn/r
Setmelanotide 16p11.2 CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide AS CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide BBS CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide MC4R CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide POMC/PCSK1/LEPR Heterozygous CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide SH2B1 CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide SMS CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide SRC1 CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityObesity or overweightn/r16n/rn/rn/rn/rn/rn/r
Setmelanotide Stage 1: Setmelanotide (Open-Label)DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayObesity or overweightn/r16n/rplacebon/r-3.94%n/rn/r
Setmelanotide Stage 2: Setmelanotide (Double-Blind)DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayObesity or overweightn/r16n/rplacebon/rn/rn/rn/r
Setmelanotide Stage 2: Placebo (Double-Blind)DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayObesity or overweightn/r16n/rThis arm is placebon/rn/rn/rn/r
Setmelanotide PlaceboPhase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Setmelanotide SetmelanotidePhase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsObesity or overweightn/rn/rn/rplacebon/rn/rn/rn/r
Setmelanotide PlaceboPhase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Setmelanotide 0.5 mgPhase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromePrader-Willi Syndrome0.5 mgn/rn/rplacebon/rn/rn/rn/r
Setmelanotide 1.5 mgPhase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromePrader-Willi Syndrome1.5 mgn/rn/rplacebon/rn/rn/rn/r
Setmelanotide 2.5 mgPhase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromePrader-Willi Syndrome2.5 mgn/rn/rplacebon/rn/rn/rn/r
Setmelanotide PlaceboPhase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromePrader-Willi Syndromen/rn/rn/rThis arm is placebon/rn/rn/rn/r
Sibutramine SibutramineSCOUTObesity or overweightn/rn/rn/rplacebon/rn/rn/rn/r
Sibutramine PlaceboSCOUTObesity or overweightn/rn/rn/rThis arm is placebon/rn/rn/rn/r
Tesofensine placebo arm48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)Obesity or overweightn/r48n/rThis arm is placebon/rn/rn/rn/r

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.